Datadog Inc vs Neurocrine Biosciences Inc — how do they compare? Datadog Inc trades at $253.15 (market cap $88.61B), while Neurocrine Biosciences Inc trades at $157.33 (market cap $16.46B). The key difference: Datadog Inc is far larger — about 5.4× Neurocrine Biosciences Inc's market cap, and Datadog Inc is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| DDOG | NBIX | |
|---|---|---|
Market Cap | $88.61B | $16.46B |
Sector | Technology | Health |
52-Week High | $288.15 | $185.50 |
52-Week Low | $102.62 | $123.10 |
Enterprise Value | $84.90B | $16.48B |
Signals from Pluang's Aura AI — not financial advice
Datadog (DDOG) trades at $260.78, up 11.48% in 24 hours, reflecting strong momentum after Q2 2026 earnings beat expectations with EPS of $0.65 versus $0.583 estimated. Revenue grew 36% year-over-year, and the company raised full-year 2026 guidance. Technical indicators show a bullish trend with support at $239 and resistance at $272, while high valuation multiples like a P/E of 493.56 signal premium pricing. Recent news highlights AI-driven growth but also insider selling and market sensitivity to guidance nuances.
The outlook remains positive due to robust revenue growth and AI adoption, but risks include elevated valuations and customer concentration. Analyst consensus is strongly bullish with an average price target of $288.55, though investors should monitor execution against high expectations and competitive pressures in the cloud monitoring space.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered as software-as-a-service, allows a client to monitor and analyze its entire IT infrastructure. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of different applications throughout their businesses.
Read more on DDOG →Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →